Biotechnology

TG Therap

TG Therap released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 204.92 M (forecast USD 201.21 M), actual EPS USD 0.1199 (forecast USD 0.2719)

TG Therap to Release FY2026 Q1 Earnings on May 6 During Market Hours (EST), Forecast Revenue USD 200.92 M, EPS USD 0.2719

TG Therapeutics Signs $750 Million Credit Agreement with Blue Owl Capital

TG Therap released FY2025 earnings on February 26 Pre-Market (EST), actual revenue USD 616.29 M (forecast USD 617.13 M), actual EPS USD 2.7699 (forecast USD 2.9805)

TG Therap released FY2025 Q4 earnings on February 26 Pre-Market (EST), actual revenue USD 192.57 M (forecast USD 193.34 M), actual EPS USD 0.1399 (forecast USD 0.3508)

TG Therap to Release FY2025 Q4 Earnings on February 26, 2026, Pre-Market EST; Forecast Revenue USD 193.34 M, EPS USD 0.3508

J.P. Morgan Analyst Downgrades TG Therapeutics Target Price to $46

TG Therapeutics to Present New Clinical Data on BRIUMVI® for Multiple Sclerosis at ACTRIMS Forum

TG Therapeutics Inc. Reports 2025 Financials and Predicts 2026 Revenue

Marex Group Invests 1,002,000 USD in TG Therapeutics

Company Announces Q3 2025 Earnings Beat, Plans Continued Commercialization of BRIUMVI

TG Therapeutics Reports Exceeding Expectations in Briumvi Revenue and Upgrading 2025 Revenue Guidance

TG Therap released FY2025 Q3 earnings on November 3 Pre-Market (EST), actual revenue USD 161.71 M (forecast USD 152.17 M), actual EPS USD 2.4299 (forecast USD 0.2201)

TG Therap released FY2025 9 Months Earnings on November 3 Pre-Market EST, Actual Revenue: USD 423.71 M, Actual EPS: USD 2.6299

TG Therapeutics Completes Phase 3 ENHANCE Trial Enrollment for BRIUMVI® New Regimen for Relapsing MS

TG Therap to Release FY2025 Q3 Earnings on November 3, Pre-Market EST; Forecast Revenue USD 152.17 M, EPS USD 0.2156

Stranahan Recommends Healthcare Industry Stocks

TG Therapeutics Announces Six-Year Data for BRIUMVI in RMS

TG Therapeutics to Present New Data on BRIUMVI® at 2025 ECTRIMS Annual Meeting

TG Therapeutics Begins Recruiting for Briumvi Phase III Trial

Big Tree Cloud

Pop Culture

VS MEDIA

Sadot

ChowChow Cloud

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Raytech

Wellchange

Battalion Oil

Tianci

TGTX

TG Therapeutics (NASDAQ: TGTX) shares surged 9.50% on Wednesday following positive Phase 1 data for a subcutaneous version of BRIUMVI in myasthenia gravis. The results, showing significant clinical improvement, have fueled optimism regarding pipeline expansion and upcoming Phase 2 trials. This development aims to broaden the drug's application beyond its current approval for multiple sclerosis, driving strong momentum despite the stock trading at extended levels relative to key moving averages.

benzinga_article

Palantir Tech

TG Therapeutics Stock Is Surging Today: What's Driving The Action?

TG Therapeutics (TGTX) sees strong stock momentum following positive BRIUMVI Phase 3 ENHANCE data and new subcutaneous formulation results. Trading at $43.37, the stock shows an implied upside to the analyst target of $48. Simply Wall St estimates a fair value of $44.43, suggesting slight undervaluation driven by revenue expansion and the upcoming subcu launch, which could significantly expand its addressable market in multiple sclerosis.

Simplywall

A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones

TG Therapeutics announced positive Phase 1 data for BRIUMVI in myasthenia gravis patients, with 82% achieving clinical improvement at Week 24. The company initiated a Phase 2 trial to evaluate BRIUMVI's efficacy in maintaining response after initial treatment with efgartigimod. Following the announcement, TGTX stock rose 3.81% to $42.51.

rttnews

TG Therapeutics Announces Positive Data From BRIUMVI Study, Initiates Phase 2 Trial; Stock Gains

GMED

AMSC

DOCU

Analysts identify mid-cap stocks offering a blend of strong growth and low valuations. Key highlights include American Superconductor and TG Therapeutics as top picks. Globus Medical and RB Global demonstrated robust revenue and earnings growth, whereas DocuSign faces challenges with slower ARR expansion. The recommended investments span diverse sectors such as biotech, REITs, financials, aerospace, and semiconductors, providing investors with varied opportunities for balanced growth.

Ritchie Bros Auctioneers

Globus Medical Inc 

American Superconductor

Docusign

Analysts highlight top mid-cap growth plays with low valuations

ABVX

NVTS

ALOY

REPL

QURE

POET

VGNT

PVLA

Abivax SA(ABVX) rose 24.34%, with a trading turnover 610.2 Million USD, and a year-to-date fell 33.2%. Navitas Semiconductor(NVTS) rose 19.26%, with a trading turnover 3.5 Billion USD, and a year-to-date rose 331.9%. REalloys(ALOY) rose 18.56%, with a trading turnover 59.4 Million USD, and a year-to-date rose 70.5%.

Top Gainers&Losers

Abivax SA

Navitas Semiconductor

REalloys

Replimune

Uniqure

POET Tech

Versigent

Palvella Therapeutics

Texas Pacific Land

Top 10 US Stock Gainers (6.3)

TG Therapeutics stock surged following news that its subcutaneous injection of Briumvi demonstrated safety comparable to intravenous administration. This development triggered an early buy signal and a bullish jump in the biotech company's shares, as investors reacted positively to the potential for increased interest and growth opportunities associated with the new route of administration.

Unusual Whales

TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish Jump